Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance.
Zhao M, Wang Y, Li L, Liu S, Wang C, Yuan Y, Yang G, Chen Y, Cheng J, Lu Y, Liu J. · 2021
Read Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. by Zhao M, Wang Y, Li L, Liu S, Wang C, Yuan Y, Yang G, Chen Y, Cheng J, Lu Y, Liu J. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7778599.txt.
Introduction
Zhao and co-authors trace how reactive oxygen in mitochondria drives kidney injury after blood flow returns. This injury, from ischemia and reperfusion, is marked by energy failure and inflammation. The team studied mice and kidney tubule cells. They focused on TFAM, a protein that keeps mitochondrial DNA in good shape.
Cutting mitochondrial reactive oxygen eased kidney damage in mice. In cells, this stress lowered TFAM and mitochondrial DNA counts. It both cut TFAM making and sped its breakdown by a shredding enzyme. Silencing TFAM erased the rescue from an antioxidant drug. Kidney samples from injured mice and patients showed the same TFAM loss. The authors name it a repair target.
Catalog record
| CREATOR | Zhao M, Wang Y, Li L, Liu S, Wang C, Yuan Y, Yang G, Chen Y, Cheng J, Lu Y, Liu J. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance By Meng Zhao, Yizhuo Wang, Ling Li, Shuyun Liu, Chengshi Wang, Yujia Yuan, Guang Yang, Younan Chen, Jingqiu Cheng, Yanrong Lu, Jingping Liu Published in: Theranostics DOI: 10.7150/thno.50905 ABSTRACT Abstract Aims: Ischemia-reperfusion injury (IRI)-induced acute kidney injury (IRI-AKI) is characterized by elevated levels of reactive oxygen species (ROS), mitochondrial dysfunction, and inflammation, but the potential link among these features remains unclear. In this study, we aimed to investigate the specific role of mitochondrial ROS (mtROS) in initiating mitochondrial DNA (mtDNA) damage and inflammation during IRI-AKI. Methods: The changes in renal function, mitochondrial function, and inflammation in IRI-AKI mice with or without mtROS inhibition were analyzed in vivo. The impact of mtROS on TFAM (mitochondrial transcription factor A), Lon protease, mtDNA, mitochondrial respiration, and cytokine release was analyzed in renal tubular cells in vitro. The effects of TFAM knockdown on mtDNA, mitochondrial function, and cytokine release were also analyzed in vitro. Finally, changes in TFAM and mtDNA nucleoids were measured in kidney samples from IRI-AKI mice and patients. Results: Decreasing mtROS levels attenuated renal dysfunction, mitochondrial damage, and inflammation in IRI-AKI mice. Decreasing mtROS levels also reversed the decrease in TFAM levels and mtDNA copy number that occurs in HK2 cells under oxidative stress. mtROS reduced the abundance of mitochondrial TFAM in HK2 cells by suppressing its transcription and promoting Lon-mediated TFAM degradation. Silencing of TFAM abolished the Mito-Tempo (MT)-induced rescue of mitochondrial function and cytokine release in HK2 cells under oxidative stress. Loss of TFAM and mtDNA damage were found in kidneys from IRI-AKI mice and AKI patients. Conclusion: mtROS can promote renal injury by suppressing TFAM-mediated mtDNA maintenance, resulting in decreased mitochondrial energy metabolism and increased cytokine release. TFAM defects may be a promising target for renal repair after IRI-AKI. Keywords: acute kidney injury, mitochondria, mtDNA, ROS, TFAM INTRODUCTION Acute kidney injury (AKI) is characterized by a rapid decline in renal function with high mortality and morbidity and is a serious health issue worldwide 1. AKI is increasing in incidence and can be caused by trauma, sepsis, surgery, or nephrotoxic drugs, and ischemia-reperfusion injury (IRI) is one of its leading causes 2. IRI disrupts the cellular redox balance and triggers excessive ROS production in the kidneys upon reperfusion, leading to a series of events that follow IRI-induced AKI (IRI-AKI) and include mitochondrial damage, energy depletion, tubular apoptosis and necrosis 3-5. Moreover, incomplete recovery from AKI can trigger renal fibrosis and thus increase the risk of chronic kidney disease (CKD) and end-stage renal failure (ESRD) 6-8. Currently, clinical interventions for AKI patients include renal replacement therapy (RRT) and nutritional supplementation. No effective therapy has been established, although many pharmacologic therapies such as diuretics, vasoactive drugs, and growth factors have been reported in animal models or preliminary clinical studies 9,10. Therefore, novel therapeutic targets for AKI are urgently needed. The pathological mechanism of IRI-AKI is complicated, and oxidative stress is considered one of the primary factors leading to the condition 11,12. The overproduction of reactive oxygen species (ROS) contributes to multiple cellular processes related to renal injury, such as cytosolic calcium overload, energy depletion, apoptosis/necrosis, and inflammation 3. Increasing evidence indicates that the mitochondrion is a main source of intracellular ROS, and ~90% of ROS are generated in mitochondria 3. Mitochondrial ROS (mtROS) are primarily produced at complexes I and III of the electron transport chain (ETC) when electrons derived from either NADH or FADH2 react with O2 13. The formation of mtROS due to proton leakage takes place under normal respiratory conditions but can be greatly enhanced in response to stress 14,15. The burst of ROS production that occurs after IRI-AKI has been shown to cause direct oxidative damage to mitochondrial proteins and lipids, thereby impairing mitochondrial bioenergetics by disrupting ETC function and increasing mitochondrial membrane permeability 16. Moreover, mtROS can also induce renal injury by activating proinflammatory signals such as Toll-like receptors (TLRs) and the NLRP3 inflammasome 17,18. Although the adverse impact of mtROS on renal function has been demonstrated, the detailed mechanism by which ROS initiate mitochondrial dysfunction and inflammation during IRI-AKI is not completely understood. Recently, mitochondrial DNA (mtDNA) damage has emerged as a hallmark feature of AKI, and mtDNA depletion has been found both in preclinical models and in human patients with AKI 19. However, the link between mtROS and mtDNA damage during IRI-AKI remains unclear. mtDNA encodes 13 protein subunits of the ETC complexes and a set of transfer and ribosomal RNAs; thus, mitochondrial function is extremely dependent on functional mtDNA. mtDNA is a double-stranded circular DNA molecule that is present in multiple copies in the mitochondrial matrix and exists in condensed DNA-protein complexes known as nucleoids. The maintenance of mtDNA stability is primarily mediated by mitochondrial transcription factor A (TFAM), an essential mtDNA packaging protein that is required for mtDNA replication and transcription 20. Under pathological conditions, disruption of TFAM could lead to mtDNA depletion and deficient mitochondrial bioenergetics 21. Based on these findings, we speculated that ROS may disrupt the stability of mtDNA, but the detailed process still requires investigation. In this study, we aimed to investigate the specific role of mtROS in mtDNA damage and inflammation during IRI-AKI. In vivo mouse IRI and in vitro cell hypoxia/reoxygenation (H/R) models were used to mimic the pathology of IRI-AKI. Changes in renal function, mitochondrial function, mtDNA maintenance, and TFAM expression were analyzed in the cell H/R and IRI-AKI mouse models with or without mtROS inhibition. The effects of mtROS on signaling pathways related to mtDNA maintenance and TFAM turnover were also analyzed. METHODS Materials and reagents The primary antibodies used in this study were purchased from the following sources: anti-Kim-1 (R&D Systems, USA); anti-TNF-α, anti-TOM20, anti-Bax (Cell Signaling Technology, Beverly, MA, USA); anti-8-OHdG, anti-dsDNA, anti-CD68 (Abcam, USA); anti-TFAM, anti-GAPDH, anti-Lon, anti-NGAL (ABclonal Biotech Co., Ltd., Cambridge, MA, USA); anti-p53, anti-ICAM, anti-ATP5a-1 (Proteintech, Rosemont, IL, USA). Mito-Tempo (MT, an mtROS scavenger) was purchased from Santa Cruz Biotechnology (CA, USA) and was dissolved in DMSO as a stock solution. Animal experiments All animal experiments were approved by the Animal Care and Use Committee of West China Hospital, Sichuan University (No. 2018198A) and were conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male C57BL/6 mice (20-25 g) were purchased from the Experimental Animal Center of Sichuan University (Chengdu, China). The animals were housed under standardized conditions with controlled temperature, humidity and 12-h cycles of light and darkness and provided with standard chow and tap water ad libitum. The mice were randomly divided into four groups (n = 6 per group): Control, IRI-AKI, IRI-AKI + MT, and IRI-AKI + vehicle. The mouse model of renal IRI injury used in this study was established as previously described 22. Briefly, the mice were anesthetized with 1% pentobarbital sodium (50 mg/kg, Merck, Darmstadt, Germany); mice with I/R injury received bilateral clamping of the renal pedicles for 30 min, and the mice in the control group received laparotomy only. To specifically inhibit the ROS burst in the kidney, an initial dose of 25 μL MT (5 μM in 0.05% DMSO in PBS) was directly injected into